Clinical benefit of lovastatin consistent across risk groups

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1264, 2000-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefit–risk assessment: the use of clinical utility index

By Ouellet Daniele

Expert Opinion on Drug Safety, Vol. 9, Iss. 2, 2010-03 ,pp. : 289-300

Informa Healthcare

Access to resources Recommend Favorite

Reirradiation of recurrent medulloblastoma: Does clinical benefit outweigh risk for toxicity?

Cancer, Vol. 120, Iss. 23, 2014-12 ,pp. : 3731-3737

Blackwell Publishing

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Pharmacotherapies for Clinical Depression in Children and Adolescents

By Renaud J. Axelson D. Birmaher B.

Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. : 59-75

Adis International

Access to resources Recommend Favorite

Test Homogeneity of Risk Difference Across Subgroups in Clinical Trials

By Zhang Lanju Yang Harry Cho Iksung

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 1, 2009-01 ,pp. : 67-76

Taylor & Francis Ltd

Access to resources Recommend Favorite

Oral sirolimus does not provide clinical benefit when administered to patients at high risk of restenosis

Inpharma, Vol. 1, Iss. 1391, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite